A perspective on progress and gaps in HIV prevention science

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1373-1378

  Kiser, Patrick F ^a   Mesquita, Pedro M M ^b   Herold, Betsy C ^b  

^a University of Utah   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDFORM; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C 31 G; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GRIFFITHSIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; IQP 0528; MARAVIROC; MEDROXYPROGESTERONE; MIV 150; NCP 7; NCP7; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; PRO 2000; PSC RANTES; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SURFACTANT; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SPERM; T LYMPHOCYTE ACTIVATION; VAGINA RING; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANAL CANAL; ANTI-HIV AGENTS; CHEMOPREVENTION; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; MALE; MEDICATION ADHERENCE; MOUTH MUCOSA; MUCOUS MEMBRANE; ORGANOPHOSPHONATES; ORGANOPHOSPHORUS COMPOUNDS; SEXUAL PARTNERS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84868600510     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0277     Document Type: Review

References (55)

1. Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410.
2. Maxmen A: Wary approval for drug to prevent HIV. Nature 2012;487(7407):283.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral mi-crobicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-1174.
4. Heffron R, Donnell D, Rees H, et al.: Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012;12(1):19-26.
5. Lewi P, Heeres J, Arien K, et al.: Reverse transcriptase inhibitors as microbicides. Curr HIV Res 2012;10(1):27-35.
6. Neurath AR, Strick N, and Li YY: Anti-HIV-1 activity of anionic polymers: A comparative study of candidate mi-crobicides. BMC Infect Dis 2002;2:27.
7. Patel S, Hazrati E, Cheshenko N, et al.: Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 2007;196(9):1394-1402.
8. Keller MJ, Mesquita PM, Torres NM, et al.: Postcoital bio-availability and antiviral activity of 0.5% PRO 2000 gel: Implications for future microbicide clinical trials. PLoS One 2010;5(1):e8781.
9. Doncel GF, Chandra N, and Fichorova RN: Preclinical assessment of the proinflammatory potential of microbicide candidates. J Acquir Immune Defic Syndr 2004;37(Suppl 3):S174-1 80.
10. Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184(4):418-428.
11. Mesquita PM, Cheshenko N, Wilson SS, et al.: Disruption of tight junctions by cellulose sulfate facilitates HIV infection: Model of microbicide safety. J Infect Dis 2009;200(4):599-608.
12. Segarra TJ, Fakioglu E, Cheshenko N, et al.: Bridging the gap between preclinical and clinical microbicide trials: Blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One 2011;6(11):e27675.
13. Wilson SS, Cheshenko N, Fakioglu E, et al.: Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: Expansion of a murine model of microbicide safety. Antivir Ther 2009;14(8):1113-1124.
14. Network MTN: Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, 2012 [cited 2012 September 4th]. Available from http://www.mtnstopshiv. org/sites/default/files/attachments/MTNStatementNov17DSMB-final.pdf.
15. Dezzutti CS, Rohan LC, Wang L, et al.: Reformulated teno-fovir gel for use as a dual compartment microbicide. J An-timicrob Chemother 2012;67(9):2139-2142.
16. Mesquita PM, Rastogi R, Segarra TJ, et al.: Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Che-mother 2012;67(7):1730-1738.
17. Stefanidou M, Herrera C, Armanasco N, et al.: Saquinavir inhibits early events associated with establishment of HIV-1 infection: Potential role for protease inhibitors in prevention. Antimicrob Agents Chemother 2012;56(8):4381-4390.
18. Romano J, Variano B, Coplan P, et al.: Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25(5):483-488.
19. Woolfson AD, Malcolm RK, Morrow RJ, et al.: Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006;325(1-2):82-89.
20. Singer R, Derby N, Rodriguez A, et al.: The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011;85(11):5504-5512.
21. Turville SG, Aravantinou M, Miller T, et al.: Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008;3(9):e3162.
22. Wilson DP, Coplan PM, Wainberg MA, et al.: The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci USA 2008; 105(28):9835-9840.
23. Johnson TJ, Srinivasan P, Albright TH, et al.: Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012;56(3):1291-1299.
24. Turpin JA, Schito ML, Jenkins LM, et al.: Topical micro-bicides: A promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors. Adv Pharmacol 2008;56:229-256.
25. Schito ML, Soloff AC, Slovitz D, et al.: Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys. Curr HIV Res 2006;4(3):379-386.
26. Miller Jenkins LM, Ott DE, Hayashi R, et al.: Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer. Nat Chem Biol 2010;6(12):887-889.
27. Zeitlin L, Pauly M, and Whaley KJ: Second-generation HIV microbicides: continued development of griffithsin. Proc Natl Acad Sci USA 2009;106(15):6029-6030.
28. Ham AS, Cost MR, Sassi AB, et al.: Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nano-particles. Pharm Res 2009;26(3):502-511.
29. Welch BD, Francis JN, Redman JS, et al.: Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol 2010;84(21):11235-11244.
30. Bouschbacher M, Bomsel M, Verronese E, et al.: Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 2008;22(11):1257-1266.
31. Ganor Y, Zhou Z, Tudor D, et al.: Within 1h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol 2010;3(5):506-522.
32. Ganor Y and Bomsel M: HIV-1 transmission in the male genital tract. Am J Reprod Immunol 2011;65(3):284-291.
33. Fischetti L, Barry SM, Hope TJ, et al.: HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 2009;23:319-328.
34. Hladik F and Hope TJ: HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6:20-28.
35. Hope TJ: Latest understanding of HIV sexual transmission. Microbicides 2008; February 25, 2008; Delhi, India, 2008.
36. Haase AT: Targeting early infection to prevent HIV-1 mu-cosal transmission. Nature 2010;464:217-223.
37. Haase AT: Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-139.
38. Mesquita P, Torres N, Segarra T, et al.: Intravaginal ring formulation of tenofovir disoproxil fumarate (TDF) facilitates rapid bioavailability of drug and protects cervical explants from HSV-2 infection. Protection from HIV: Targeted Intervention Strategies, Keystone Symposia; March 20-25; British Columbia, Canada, 2011.
39. Mesquita P, Rastogi R, Johnson T, et al.: Intravaginal ring delivery of the pyrimidinedione IQP-0528 results in protective concentrations in vaginal biopsies of pigtailed macaques, novel models to assess pharmacokinetics/ pharmacodynamics. 19th Conference on Retroviruses and Opportunistic Infections; March 5-8; Seattle, WA, 2012.
40. Sharkey DJ, Macpherson AM, Tremellen KP, et al.: TGF-beta mediates proinflammatory seminal fluid signaling in human cervical epithelial cells. J Immunol 2012;189(2):1024-1035.
41. Sharkey DJ, Macpherson AM, Tremellen KP, et al.: Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007;13(7):491-501.
42. Sharkey DJ, Tremellen KP, Jasper MJ, et al.: Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012;188(5):2445-2454.
43. Kiser PF, Johnson TJ, and Clark JT: State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012;14(1):62-77.
44. Naranbhai V, Abdool Karim SS, Altfeld M, et al.: Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012;206(7):993-1001.
45. Vishwanathan SA, Guenthner PC, Lin CY, et al.: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011;57(4):261-264.
46. Madan RP, Carpenter C, Fiedler T, et al.: Altered biomarkers of mucosal immunity and reduced vaginal lactobacillus concentrations in sexually active female adolescents. PLoS One 2012;7(7):e40415.
47. Low N, Chersich MF, Schmidlin K, et al.: Intravaginal practices, bacterial vaginosis, and HIV infection in women: Individual participant data meta-analysis. PLoS Med 2011;8(2):e1000416.
48. Cohen CR, Lingappa JR, Baeten JM, et al.: Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: A prospective cohort analysis among African couples. PLoS Med 2012;9(6):e1001251.
49. Mitchell C, Hitti J, Paul K, et al.: Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2011;27(1):35-39.
50. Shacklett BL and Anton PA: HIV infection and gut mucosal immune function: Updates on pathogenesis with implications for management and intervention. Curr Infect Dis Rep 2010;12(1):19-27.
51. Patterson KB, Prince HA, Kraft E, et al.: Penetration of te-nofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3(112):112re114.
52. Robbins BL, Srinivas RV, Kim C, et al.: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(iso-propyloxy-methylcarbonyl)PMPA. Antimicrob Agents Che-mother 1998;42(3):612-617.
53. Gao WY, Agbaria R, Driscoll JS, et al.: Divergent anti-human immunodeficiency virus activity and anabolic phosphory-lation of 2', 3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269(17):12633-12638.
54. Garcia-Lerma JG, Aung W, Cong ME, et al.: Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011;85(13):6610-6617.
55. Cihlar T, Ho ES, Lin DC, et al.: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):641-648.